Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10

[1]  B. Monk,et al.  Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  N. Pavlidis,et al.  BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside , 2022, Cancers.

[3]  E. Swisher,et al.  CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Antonios Revythis,et al.  Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer , 2022, International journal of environmental research and public health.

[5]  Aruni Ghose,et al.  Applications of Proteomics in Ovarian Cancer: Dawn of a New Era , 2022, Proteomes.

[6]  M. Devouassoux‐Shisheboran,et al.  The Increasing Prognostic and Predictive Roles of the Tumor Primary Chemosensitivity Assessed by CA-125 Elimination Rate Constant K (KELIM) in Ovarian Cancer: A Narrative Review , 2021, Cancers.

[7]  S. Lheureux,et al.  The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas. , 2021, Cancer treatment reviews.

[8]  A. Tinker,et al.  751P Survival prognostic and surrogate values of the early modeled CA-125 KELIM in newly diagnosed advanced ovarian cancer: Data from the GCIG meta-analysis group , 2021, Annals of Oncology.

[9]  O. Trédan,et al.  733P Bevacizumab (Bev), olaparib (Ola) and durvalumab (Durva) in patients with recurrent advanced ovarian cancer (AOC): The GINECO BOLD study , 2021, Annals of Oncology.

[10]  I. McNeish,et al.  Differential benefit from fractionated dose-dense first-line chemotherapy for epithelial ovarian cancer (EOC) according to KELIM-evaluated tumor primary chemosensitivity: Exploratory analyses of ICON-8 trial. , 2021 .

[11]  Natalie Y L Ngoi,et al.  The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it? , 2021, ESMO open.

[12]  A. Tinker,et al.  Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2) , 2021, Nature Communications.

[13]  J. Ledermann,et al.  The Systemic Treatment of Recurrent Ovarian Cancer revisited. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  R. Kristeleit,et al.  Rucaparib versus chemotherapy in patients with advanced , relapsed ovarian cancer and a deleterious BRCA mutation : Efficacy and safety from ARIEL 4 , a randomized phase III study Presenting , 2021 .

[15]  S. Shah,et al.  ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  B. Lin,et al.  Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy. , 2020, Life sciences.

[17]  M. van der Aa,et al.  847P The prognostic value of chemosensitivity, estimated by the modeled CA-125 KELIM, in ovarian cancer patients treated with neo-adjuvant chemotherapy in the Netherlands , 2020 .

[18]  E. Kohn,et al.  PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Gulati,et al.  Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. , 2020, The Lancet. Oncology.

[20]  I. Ray-Coquard,et al.  CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial , 2020, Clinical Cancer Research.

[21]  D. Timmerman,et al.  ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  I. Ray-Coquard,et al.  Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study , 2019, Clinical Cancer Research.

[23]  F. Saad,et al.  Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Cesar M. Castro,et al.  Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. , 2017, Gynecologic oncology.

[25]  H. Chung,et al.  Predictive value of circulating tumor cells (CTCs) captured by microfluidic device in patients with epithelial ovarian cancer. , 2017, Gynecologic oncology.

[26]  Anne Floquet,et al.  Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. , 2017, The Lancet. Oncology.

[27]  Ayala Hubert,et al.  Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. , 2016, Gynecologic oncology.

[28]  Ayala Hubert,et al.  Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  A. Oza,et al.  The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study). , 2013, Gynecologic oncology.

[30]  B Richter,et al.  Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer , 2011, British Journal of Cancer.

[31]  V. Gebski,et al.  Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer. , 2011, Journal of the National Cancer Institute.

[32]  M. Parmar,et al.  Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG) , 2010, International Journal of Gynecologic Cancer.

[33]  E Comets,et al.  Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey. , 2007, British journal of clinical pharmacology.

[34]  E. Eisenhauer,et al.  Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer) , 2005 .

[35]  E N Jonsson,et al.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. , 1999, Computer methods and programs in biomedicine.

[36]  H E Lambert,et al.  Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.